Zimbabwe has rejected a significant American health deal worth $367m (272 million pounds) spanning five years over Washington's insistence on sensitive biological samples.
This rejection became public following a government memo from December was disclosed, which showed President Emmerson Mnangagwa believed the agreement was "lopsided".
An official representative later explained that the US was requesting biological samples for research and profit but refused to share the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable process of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged further talks to reach a deal acceptable to all parties so the country's vital HIV programme can proceed.
Wider Context
This development follows a comparable case in Kenya, where a high court halted a similar deal with the US following concerns were filed about the security of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump stated its spending was "inefficient" and his government was seeking direct bilateral deals to boost openness and responsibility.
Based on statements, Sixteen African countries have to date signed these new health pacts, representing more than $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy through American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, without any equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might result from that shared data," Mangwana explained.
"Put simply, our nation would supply the raw materials for medical research with no assurance that the end products would be available to our people if a future pandemic emerge."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting frameworks previously established via the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This mechanism is intended to guarantee that when a nation provides its information, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections over the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing dialogue with our American counterparts on how subsequent co-operation could be structured in a manner that honours the independence and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but urged that negotiations should continue considering a large portion of the country's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, including those relating to data governance or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," the group said.
The situation highlights the continuing tensions between accepting much-needed international aid and safeguarding local interests in an ever more data-driven world.